Three decades after its birth, New York's Silicon Alley has matured into a distinct tech ecosystem, anchored by profitability, cross-industry ties, and resilience through multiple booms and busts.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Seven Wisconsin employers filed WARN notices in January, yet the state's unemployment rate held steady at a low 3.1%. Economists point to a cooling but stable labor market, with significant workforce changes driven by retirements and sectoral shifts.
As housing costs squeeze employees nationwide, a new wave of benefits is emerging. Fintech startup Oro has raised $3 million to help employers offer housing assistance, signaling a major shift in corporate wellness strategies.
Realty Income, the 'Monthly Dividend Company,' has now made over 650 consecutive monthly payments to shareholders. While its financials show a robust cushion, rising interest rates and a shifting retail landscape pose questions about the sustainability of its legendary income stream.
TOPEKA — Kansas's popular Learning Quest 529 savings plans are set for a significant upgrade next month, promising families new investment options, enhanced planning tools, and reduced management fees under a new administrator, State Treasurer Steven Johnson announced.
Phillip Securities initiates coverage of Palantir Technologies with a Buy rating, citing its AI software segment's robust growth and significant market expansion potential. A new partnership with Innodata aims to enhance Palantir's rodeo analysis platforms through advanced data services.
IBM intensifies its focus on the enterprise AI market with the launch of its governed deployment platform, a strategic collaboration with e& for regulated sectors, and the appointment of PepsiCo's Ramon Laguarta to its board of directors.
While the Schwab U.S. Dividend Equity ETF (SCHD) remains a cornerstone for income investors, a new analysis highlights several compelling alternatives that address its potential gaps in sector exposure, yield, and international diversification.
Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.
As Bitcoin and major altcoins extend losses, the native token of decentralized exchange Hyperliquid has surged over 40% in a week, with its novel permissionless markets hitting record volumes, prompting some to label it a rare 'defensive' crypto asset.
Augusto Blacker Miller, a controversial figure from Peru's Fujimori era, has died in a Rio de Janeiro prison hospital. The 80-year-old, arrested in Brazil last December on an Interpol warrant, succumbed to cardiorespiratory arrest, reigniting debates about justice, aging detainees, and cross-border legal accountability.
Investment firm Ashva Capital Management highlights Advanced Micro Devices (AMD) in its latest investor letter, citing the chipmaker's disciplined execution as a cornerstone for enduring growth, even as the fund's overall 2025 returns trailed major indices.
Millions of seniors received a 2.8% Cost-of-Living Adjustment this January, but soaring Medicare premiums and a flawed inflation formula mean their real purchasing power continues to erode, highlighting a systemic crisis for retirees.
With pharmaceutical companies increasingly deploying AI in direct-to-consumer platforms, the regulatory landscape remains fragmented. In the absence of comprehensive federal action, states are stepping in with disparate laws to address privacy and safety concerns, creating a complex compliance challenge for the industry.
A retired couple seeks to protect their life savings from the soaring costs of long-term care. With a $100,000 IRA and a family trust in place, they question if it's enough to prevent asset depletion, navigating the complex intersection of Medicaid rules, estate planning, and quality-of-life concerns.
Lawmakers reconvene Monday as House GOP leadership pushes for rapid passage of a stopgap funding bill to prevent a prolonged partial government shutdown, with tensions high over border security provisions.
A pervasive culture of silence around estate planning is setting the stage for confusion and conflict as trillions in assets prepare to change hands. Experts warn that avoiding 'the talk' is a disservice to both generations.
